The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

Compared with patients with psoriatic arthritis (PsA) receiving placebo, those receiving secukinumab demonstrated a significant reduction in bone erosion volume and improvement in partial healing ...